S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News

$3.96
+0.29 (+7.90%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.47
$4.01
50-Day Range
$2.92
$7.48
52-Week Range
$2.55
$9.65
Volume
3.85 million shs
Average Volume
1.01 million shs
Market Capitalization
$378.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

ARS Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
203.0% Upside
$12.00 Price Target
Short Interest
Bearish
10.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.34mentions of ARS Pharmaceuticals in the last 14 days
Based on 24 Articles This Week
Insider Trading
Acquiring Shares
$23.25 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.81) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

612th out of 968 stocks

Pharmaceutical Preparations Industry

279th out of 445 stocks


SPRY stock logo

About ARS Pharmaceuticals (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.

SPRY Price History

SPRY Stock News Headlines

Forget NVDA. Buy this A.I. stock instead
Dozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... MORE HERE...
What's Going On With ARS Pharmaceuticals Stock Today?
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
Forget NVDA. Buy this A.I. stock instead
Dozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... MORE HERE...
Analyst Expectations for ARS Pharmaceuticals's Future
Wedbush Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals Inc.
See More Headlines
Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPRY Company Calendar

Last Earnings
8/10/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRY
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+233.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-34,680,000.00
Pretax Margin
-24,357.53%

Debt

Sales & Book Value

Annual Sales
$1.32 million
Book Value
$2.90 per share

Miscellaneous

Free Float
61,546,000
Market Cap
$344.05 million
Optionable
Optionable
Beta
-0.12
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Richard Lowenthal M.B.A. (Age 57)
    M.S., MSMSEL, Founder, Pres, CEO & Director
    Comp: $908.83k
  • Dr. Sarina Tanimoto M.B.A. (Age 55)
    M.D., Co-Founder & Chief Medical Officer
    Comp: $748.97k
  • Mr. Eric Karas (Age 51)
    Chief Commercial Officer
    Comp: $618.61k
  • Dr. Robert Bell Ph.D.
    Co-Founder & Chief Science Officer
  • Ms. Kathleen D. Scott CPA
    Chief Financial Officer
  • Mr. Brian T. Dorsey M.S. (Age 55)
    Chief Operations Officer
  • Mr. Alexander A. Fitzpatrick Esq. (Age 56)
    Chief Legal Officer & Sec.
  • Mr. Daniel Relovsky
    Sr. VP of Marketing
  • Mr. Harris Kaplan M.B.A. (Age 71)
    MBA, Exec. VP of Commercial Strategy
  • Mr. Justin Chakma (Age 33)
    Chief Bus. Officer & Sec.













SPRY Stock - Frequently Asked Questions

Should I buy or sell ARS Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SPRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRY, but not buy additional shares or sell existing shares.
View SPRY analyst ratings
or view top-rated stocks.

What is ARS Pharmaceuticals' stock price forecast for 2023?

4 analysts have issued 12 month price targets for ARS Pharmaceuticals' stock. Their SPRY share price forecasts range from $5.00 to $17.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for SPRY
or view top-rated stocks among Wall Street analysts.

How have SPRY shares performed in 2023?

ARS Pharmaceuticals' stock was trading at $8.53 on January 1st, 2023. Since then, SPRY shares have decreased by 57.8% and is now trading at $3.60.
View the best growth stocks for 2023 here
.

When is ARS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SPRY earnings forecast
.

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.01 million for the quarter.

What is ARS Pharmaceuticals' stock symbol?

ARS Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPRY."

Who are ARS Pharmaceuticals' major shareholders?

ARS Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Rubric Capital Management LP (2.95%), BlackRock Inc. (2.39%), Sectoral Asset Management Inc. (1.32%), Woodline Partners LP (0.70%), Geode Capital Management LLC (0.69%) and Royce & Associates LP (0.49%). Insiders that own company stock include Kathleen D Scott, Laura Shawver and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARS Pharmaceuticals' stock price today?

One share of SPRY stock can currently be purchased for approximately $3.60.

How much money does ARS Pharmaceuticals make?

ARS Pharmaceuticals (NASDAQ:SPRY) has a market capitalization of $344.05 million and generates $1.32 million in revenue each year.

How can I contact ARS Pharmaceuticals?

ARS Pharmaceuticals' mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The official website for the company is ars-pharma.com. The company can be reached via phone at 206-456-2900 or via email at ir@silverbacktx.com.

This page (NASDAQ:SPRY) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -